In Focus channel feed

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

5 days ago
R&D
Cell/Gene Tx

The in­side sto­ry of how Sali­o­Gen, a start­up try­ing to wran­gle ‘jump­ing genes’ to make med­i­cines, fell apart

Last week
Startups

US drug­mak­ers in­creas­ing­ly look abroad for clin­i­cal tri­als as con­fi­dence in FDA wa­vers

Last week
Pharma

Pri­mate re­searchers cope with un­cer­tain­ty as NIH ap­peals for pay­ment cuts in court 

5 weeks ago
R&D
Pharma

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

Last month
R&D

Il­lu­mi­na was built on DNA. Its fu­ture could be bi­ol­o­gy’s next big wave

Last month
Diagnostics

A Cal­i­for­nia health tech com­pa­ny is let­ting AI run med­ical vis­its, from in­take to di­ag­no­sis

Last month
AI
Health Tech

Ahead of FDA de­ci­sion, Al­ny­lam faces the big ques­tion: Can it make mon­ey?

Last month
Pharma
FDA+

In­side NYC’s wait­list-on­ly health tech club, where young pro­fes­sion­als find both friends and jobs

2 months ago
Health Tech

Trump’s sci­ence crack­down hits rare dis­ease re­search: ‘We need to sit down with Elon Musk’

2 months ago
Financing

Can Bill An­der­son save Bay­er?

2 months ago
People
Pharma

Will CRISPR mat­ter?

2 months ago
R&D
Special

Drug­mak­ers seize on bio­mark­ers to test the FDA's rare dis­ease shift

3 months ago
R&D
FDA+

Trump blog: Fed­er­al agen­cies must give jobs back to fired pro­ba­tion­ary work­ers, judge rules

3 months ago
Pharma
FDA+

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

3 months ago
R&D
China

Broad In­sti­tute pa­per of­fers po­ten­tial new frame­work for treat­ing Hunt­ing­ton’s dis­ease

3 months ago
R&D

How a du­ty to spend wise­ly on work­er ben­e­fits could loosen PBM­s' grip on drug prices

4 months ago
Pharma
Law

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

5 months ago
AI

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

5 months ago
R&D
Discovery

Law­mak­ers are pok­ing holes in phar­ma's fa­vorite new way to mar­ket med­i­cines

5 months ago
Pharma
Health Tech

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

5 months ago
R&D
Pharma

Yorvipath’s ap­proval show­cas­es bio­phar­ma’s in­ter­est in rare en­docrine dis­or­der

6 months ago
Startups
R&D

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

6 months ago
FDA+

Is there room for MASH drugs in a GLP-1 world?

6 months ago
R&D
Pharma
1234 Next page Last page
A service from the Financial Times
OSZAR »